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There is a general lack of awareness regarding sickle cell trait in the field of athletics.  While 
sickle cell trait is usually considered a benign condition, there have been reports of serious 
complications during extreme conditions (i.e. high altitude or hot temperatures) among 
competitive athletes.  In June 2009, the National Collegiate Athletic Association (NCAA) 
recommended that all of its student athletes determine their sickle cell trait status, if unknown.  
Testing athletes for sickle cell trait has possible undesirable implications, such as stigmatization 
and discrimination against athletes with sickle cell trait.  This project aimed to prevent these 
negative implications by developing a novel program to provide sickle cell education, testing, 
and pre/post-test counseling for students in collegiate athletic programs. 
The Pediatric Sickle Cell Program at Children’s Hospital of Pittsburgh (CHP) 
collaborated with the University of Pittsburgh in July of 2009 to facilitate voluntary testing of 
student athletes for sickle cell trait.  Our program provided pre-test counseling, testing within the 
University of Pittsburgh’s athletic training facilities for each student athlete, and post-test 
counseling, regardless of trait status.  We met with athletic department staff to provide sickle cell 
trait education, methods to prevent exercise-related sudden death, and emphasized the 
importance against stigmatizing student athletes with sickle cell trait.   
Testing and education were received well by both coaches and athletes.  In total, we 
tested 79 student athletes; two of which were found to have sickle cell trait.  Our program in the 
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future plans to work with the University of Pittsburgh Athletic Department again and expand 
testing protocols to other universities in the area.  In addition, future studies will assess the 
student athletes’ experience during testing and reasons why some athletes chose not to be tested.  
The public health significance of this project is two-fold: to create a testing protocol and 
educational plan that can be individualized for the needs of a university, while maintaining the 
autonomy and privacy of the student athletes, and ensuring beneficence and non-malfeasance.  In 
addition, the project raised awareness of sickle cell trait in the field of athletics, which will 
prevent sudden death among otherwise healthy, young athletes.   
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1.0  INTRODUCTION 
Sickle cell trait is present in approximately 1 out of every 12 African-Americans and is generally 
considered a benign condition.1 Those with sickle cell trait have one copy of the sickle 
hemoglobin gene and one copy of the normal hemoglobin gene.  Under extreme conditions, 
namely dehydration and low blood oxygen levels, both of which can be present during periods of 
intense exertion, sickle red cells can accumulate in the bloodstream, a process referred to as 
exertional sickling.  These sickle red cells can block blood vessels, leading to physical collapse 
and rapid muscle breakdown, rhabdomyolysis, due to localized oxygen deprivation.  In some 
cases, this process can lead to sudden death in an otherwise young, healthy athlete.  There have 
been nine suspected deaths in middle school, high school, and college athletes over the past 
seven years alone.2   
In July of 2009, the National Collegiate Athletic Association (NCAA) strongly 
recommended that its member universities and colleges screen all athletes for sickle cell trait.3  
As with any genetic testing, it is imperative that sickle cell trait screening be performed in a 
manner consistent with the hallmarks of genetic testing, autonomy, beneficence, accuracy and 
privacy.  Screening must ensure that student athletes are not stigmatized or otherwise 
discriminated against as a result of their sickle cell trait status.  Additionally, appropriate 
education to both student athletes and athletic staff needs to be provided so that proper action can 
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be taken to prevent further deaths from occurring.  Merely knowing a student athlete’s trait status 
is inadequate to prevent sudden death. 
This project aimed to provide sickle cell trait testing to student athletes at the University 
of Pittsburgh in a manner that maintained the hallmarks of genetic testing, and ensure that no 
athletes were discriminated against due to their newly identified trait status.  The public health 
relevance of this effort is in its aims to educate and promote awareness of sickle cell trait in the 
field of collegiate athletics, a setting in which the importance of knowing a student athlete’s trait 
status has previously been overlooked, and potentially misunderstood. 
Services to provide testing for sickle cell trait for the student athletes at the University of 
Pittsburgh were initiated at the beginning of the Fall 2009 season.  Student athletes were offered 
sickle cell trait testing on a voluntary basis.  Those students who elected for testing received pre-
test genetic counseling as well as sickle cell education before phlebotomy.  Hemoglobinopathy 
evaluation was performed in the clinical labs at Children’s Hospital of Pittsburgh of UPMC.  
Results were reported to the student athletes via telephone, at which point post-test counseling 
was provided.  A group of coaches, athletic trainers, and athletic staff at the university were 
given an educational presentation regarding the history of sickle cell disease and trait, the 
physiological explanation for sudden-death in sickle cell trait carriers, methods to reduce risk of 
sudden-death in the student athlete, and the appropriate actions to take when an athlete with 
sickle cell trait collapses suddenly.  It is our aim that by promoting responsible sickle cell testing 
and education at the university level future sudden death due to exertional sickling can be 
prevented. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 SICKLE CELL DISEASE 
Sickle cell disease is an autosomal recessive inherited hematological disorder, most commonly 
affecting those of African decent.  The disorder’s name is derived from the presence of 
abnormally shaped erythrocytes, red blood cells, which instead of being round and soft, are 
shaped like a sickle and hard.  It is defined by the presence of hemoglobin S (Hb S), abnormal 
hemoglobin resulting from the substitution of valine for glutamic acid at amino acid position six 
in the ß-hemoglobin chain, produced by the hemoglobin ß gene (HBB).  Hemoglobin S is much 
less soluble than normal hemoglobin (Hb A) when deoxygenated, causing polymerization of Hb 
S in erythrocytes, resulting in the sickle shape.4 Even when blood is saturated with oxygen, Hb S 
aggregates may be sufficient to alter the rhologic properties of erythrocytes, which can in turn 
occlude end arterioles, resulting in chronic hemolysis and microinfarction of a variety of body 
tissues.  This process ultimately leads to vaso-occlusive crisis and irreversible tissue damage.4 
The incidence of sickle cell disease in the United States is one in every 500 African-Americans 
(compared to one in 2,000-10,000 white Americans).  While less prevalent, sickle cell disease 
can also be found in the Middle East, Greece, India, and occasionally in Caucasians due to 
admixture over centuries.5 Sickle cell disease is an umbrella term for a group of disorders 
characterized by the presence of one Hb S allele and a second, disease-causing allele.  Sickle cell 
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anemia is the most frequent of these disorders and arises when both HBB genes have the Hb S 
mutation. 
2.1.1 Molecular and Genetic Basis of Sickle Cell Disease 
Sickle cell disease has a long history, starting in 1910 with the discovery of sickled cells by 
James Herrick in the blood of an anemic African graduate student who experienced recurrent 
pain; however, the cause was not determined until 1927 that the transformation to sickled cells 
occurred in response to a lack of oxygen.6, 7 Earlier, in 1923, sickling was incorrectly classified 
as an autosomal dominant trait.  This assumption was not corrected until 1949, at which point it 
was determined that heterozygosity for the sickle cell gene resulted in sickle cell trait and 
homozygosity resulted in sickle cell anemia.8 Linus Pauling and his colleagues used 
electrophoresis to demonstrate that hemoglobin from patients with sickle cell anemia showed an 
abnormally slow rate of migration, and that their parents had both normal and abnormal 
migrating hemoglobin.9 It was discovered soon after, that other abnormal hemoglobins could be 
identified using this method.  Eventually, sickle hemoglobin was labeled as Hb S, normal 
hemoglobin as Hb A and additional variants were assigned letters of the alphabet (e.g. Hb C), 
until all the letters had been exhausted, at which point they were labeled by the geographic 
location in which they had been discovered.10 
Sickle cell disease is a general term to describe the sickling of red blood cells that occur 
when they are deoxygenated.  Sickle cell anemia, the most common, is the specific term for 
homozygosity of abnormal hemoglobin resulting from the substitution of valine for glutamic acid 
at amino acid position six in the HBB gene.4 Other sickle cell disorders in which sickling 
produces a significant clinical phenotype are sickle cell hemoglobin C disease, sickle cell 
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hemoglobin D disease and sickle cell ß-thalassemia.  While there is much overlap between the 
clinical manifestations and severity of these disorders, sickle cell anemia tends to be the most 
severe.10 
While it is estimated that approximately 8% of African-Americans have hemoglobin S 
trait, the prevalence is much greater in tropical Africa, ranging from 20-40% of the population 
depending on location within the region.10 The high prevalence of hemoglobin S trait 
corresponds to regions of the world where falciparum malaria is common; leading numerous 
studies to deduce that the trait is protective against the parasite.11, 12 Studies indicate that this 
advantage is present only in young children with sickle cell trait.  While these children can 
become infected, the parasite count remains low. The exact mechanism of resistance has yet to 
be elucidated, however it has been hypothesized that parasitic infection of the erythrocytes with 
Hb S causes them to sickle, which would lead them to be cleared (destroyed) by the spleen, 
thereby ridding the body of infected cells.13 
The role of hemoglobin in the body is to transport oxygen through the bloodstream from 
the lungs to the various tissues of the body and carbon dioxide from these tissues back to the 
lungs.  Additionally, hemoglobin destroys nitric oxide molecules.  Two pairs of polypeptide 
chains make up each molecule of hemoglobin, two α-chains and ß-chains.  The conformation, 
and therefore oxygen affinity, of the hemoglobin molecule changes as it gains and loses 
oxygen.10 When Hb S molecules become deoxygenated, they have a strong tendency to 
aggregate.  Once a few molecules of hemoglobin aggregate, they form a “seed” on which more 
hemoglobin aggregates on rapidly.  This sickling process is characterized by a long delay, which 
is very dependent on temperature and concentration of aggregates.14 The deoxygenated Hb S 
turns into a firm gel, causing the erythrocyte’s form to change from round to the characteristic 
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sickle shape.  If a erythrocyte repeatedly changes from a sickle to round shape, the membrane is 
affected, causing the cell to permanently stay in the sickle formation.15 Sickled cells have a short 
intravascular life span of 10 to 20 days, compared to the 120 days of normal erythrocytes, and 
this reduction in their life span results in anemia.10 
 
Figure 1: Genetics and Physiology of Erythrocyte Sickling16 
2.1.2 Factors Which Contribute to Sickling of Erythrocytes  
There is wide clinical variety in the presentation of sickle cell disease, and it is thought that this 
is due to a large number of inherited and acquired factors.  Deoxygenation is the most important 
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factor determining the occurrence of sickling in erythrocytes with Hb S; therefore, situations that 
decrease oxygen levels in the blood may pose a risk (e.g. decreased cardiac function, higher 
elevations, exercise, scuba diving).10 While there have been some reports of pain crises or 
splenic infarctions in patients with sickle cell anemia while flying aboard a commercial aircraft, 
there is no evidence that individuals with sickle cell trait are at any risk.17, 18 Additionally, the 
speed at which deoxygenation occurs may play a role, as in vitro studies suggest that 
instantaneous deoxygenation can cause more rapid sickling.19 
Oxygen tension varies throughout the body and is especially low in areas where there is 
vascular stasis, slowing of the blood flow.  While no body site is immune from vaso-occlusion, a 
blocking of blood vessels as a result of sickling, certain sites are more prone than others; such as 
the spleen, kidneys and phallus, where hypoxemia occurs and sickling can result.  Sickling in 
erythrocytes is not instantaneous and a period of two to four minutes is needed for the 
transformation to occur.  It is usual for erythrocytes to only spend 10-15 seconds in venous 
circulation; however, in other areas where vascular stasis is more common sickling can occur.20 
Blood viscosity is increased by sickled cells, resulting in further slowing of the blood circulation 
and thus more sickling, leading to possible vascular occlusion and infarction.  Ultimately, this 
serious of events can lead to tissue death and pain crisis.10 
While a causal relationship has not been confirmed, it has been observed that cold 
temperatures may initiate sickling, possibly due to the vasoconstriction that occurs during cold 
temperatures.21 Close to freezing temperatures however in vitro, have been shown to inhibit 
sickling.22 Increased blood acidity, referred to as acidosis, may precipitate sickling, as it 
produces conditions which favor the deoxygenated hemoglobin S state.23 Infection can be a 
contributor to vaso-occlusive crises due to a combination of potential factors that favor sickling 
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such as dehydration caused by the associated fever, vomiting and diarrhea, acidosis caused by 
decreased food intake, and pneumonia resulting in hypoxemia.10, 24 
2.1.3 Clinical Manifestations of Sickle Cell Disease 
While individuals with sickle cell disease are generally healthy much of the time, they can 
experience intermittent and sudden vaso-occlusion, aplastic, sequestration or hemolytic crises.  
Vaso-occlusive crisis, referred to as a pain crisis, is characteristic of sickle cell disease and is the 
most common out of the four crises.  Due to the clinical variability of the disease, these pain 
crises range in frequency from daily to less than one a year, depending on the patient.25 These 
crises affect the bones, the chest and the abdomen, but may occur in any tissue. Other 
manifestations of sickle cell disease may include: sickle cell dactylitis (swelling of the dorsal 
surfaces of the hands and/or feet) in children (especially under the age of four), splenomegaly 
and repeated splenic infarctions, jaundice, hepatomegaly, sickle retinopathy, leg ulcers, 
priapasm, susceptibility to infection, stroke, and later in life, renal failure.10 With regular and 
thorough medical care, the current life expectancy for individuals with sickle cell disease is mid-
forties.26 
2.2 SICKLE CELL TRAIT 
It is estimated that approximately 8% African-Americans in the United States, and 0.05% of 
white Americans have sickle cell trait.  Individuals with sickle cell trait consistently have a 
hemoglobin composition of less than 50% HbS.27 The amount of Hb S varies between 
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individuals due to genetic and environmental factors, and ranges somewhere between 20-45%.28, 
29 Intracellular polymerization of Hb S in persons with sickle cell trait can not be detected in 
vitro, unless oxygen tensions are decreased to below physiological levels.30 
2.2.1 Health Implications 
In contrast to a sickle cell disorder, sickle cell trait has not been considered a disease, instead 
being regarded as an asymptomatic condition.  There is evidence to support this, including the 
fact that sickle cell trait does not have a significant impact on life expectancy.1 As discussed 
above, sickle cell trait can actually be beneficial, as it confers childhood protection against 
falciparum malaria. When individuals with sickle cell trait are compared to controls, there is no 
difference in the age, duration, or pattern of hospital admissions.31, 32 Despite this evidence, there 
are reports of definite associations between specific health complications and sickle cell trait.27, 
33-44 
2.2.1.1 Renal and Urinary Tract Complications 
Studies indicate that there is an increased prevalence of urinary infections in persons with 
sickle cell trait, particularly in women during pregnancy.27, 33 The most frequent complications of 
sickle cell trait is hematuria, both gross (red blood cells visible in the urine, giving it a red or 
dark brown appearance), and microscopic (red blood cells visible only under a microscope).34, 35 
There are a variety of causes of hematuria including kidney stones and lower urinary tract 
neoplasms.  In individuals with sickle cell trait the causes of most concern are papillary necrosis 
and renal medullary carcinoma.   
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 A study released in 1979 observed that among African-American males in Veterans 
Administration Hospitals, 4% were admitted for hematuria, while only 2% of patients with 
normal hemoglobin were admitted for the same problem.31 The authors speculated that among 
that 4%, it was reasonable to estimate that the cause in half of these cases were unrelated to the 
patients’ sickle cell trait status.  Renal papillary necrosis has classically been associated with 
sickle cell disease, as well as analgesic abuse and diabetic urinary tract infections, and refers to 
ischemic damage to the renal medulla.34   
Painless gross hematuria is the common presentation of renal papillary necrosis.  The 
exact mechanism has yet to be elucidated, but physiologically the renal medulla provides a 
particular environment of dehydration, acidosis, decreased oxygen tension and high osmolarity, 
which are all well-established triggers of red blood cell sickling.  Furthermore, the blood flow is 
naturally slower in the vasa recta (capillaries of the kidneys) to provide ample time for water to 
be drawn out of the red blood cells.  As a consequence, this process increases intracellular 
concentration of sickle cell hemoglobin, which can precipitate sickling, thereby increasing the 
viscosity of the blood.  More viscous blood will flow even slower, ultimately leading to the 
formation of microthrombi, which can cause microinfarctions that damage the vasa reta and may 
lead to isothenuria, a condition in which the kidneys can no longer dilute or concentrate urine.   
The most serious association, although extremely rare, is the occurrence of renal 
medullary carcinoma, which is a highly aggressive tumor.  First described in young patients with 
sickle cell trait these tumors arise from the epithelium of the distal collecting ducts and mostly 
form in the right kidney.36 These tumors are seen nearly exclusively in young individuals with 
sickle cell trait.  While only 120 cases have been reported, 119 of these cases have been in 
patients with positive sickling status.35 The median age of diagnosis is 22 years, with a ratio of 
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3:4 males before the age of 24, and equal gender frequency after age 24.  Unfortunately, only 3 
patients have reportedly survived the disease and the median survival is 15 weeks, demonstrating 
the aggressiveness of the tumor.35 
2.2.1.2 Splenic Infarction 
While splenic function is considered normal in sickle cell trait, splenic infarction, an 
episode in which tissue death occurs due to oxygen shortage, may occur at high altitudes.37 There 
have been numerous reported cases amongst persons with sickle cell trait of splenic infarctions in 
high altitude areas such as the Andes and Rocky Mountains, and less frequently when 
hypoxemia is not an issue.17, 38-45 A majority of the cases have occurred in men who were not of 
African decent.46 Most cases tend to be mild; however, some patients present with acute splenic 
syndrome, which can result in splenic rupture requiring an emergency splenectomy.  Normally 
splenic infarction can be managed with adequate hydration, analgesia, rest, oxygen and other 
necessary supportive measures.35 
2.2.2 Sickle Cell Trait and Exercise 
It has been shown that following exercise, sickle cell trait carriers can experience an increase of 
sickled cells.47 The phenomenon is often referred to as exertional sickling. The presence of 
sickled cells after physical exertion appears especially when higher altitudes are simulated.48 In 
1989, Martin and colleagues demonstrated that the proportion of reversibly sickled cells in 
venous blood, as measured in vivo in a limb, increased during exercise at an altitude of 1270 
meters (~4,167 feet) and was even more so pronounced at 4000 meters (~13,124 feet).48 
Hypoxemia caused by increased altitude alone does not always produce sickling in those with 
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sickle cell trait.  Sickling did not occur when four subjects with sickle cell trait were exposed to a 
simulated altitude of 3250 meters (10,000 feet) or higher for 80-85 minutes, nor did it occur in a 
study with one subject at simulated 4300 meters (13, 200 feet) 30 minutes.  More extreme 
altitudes of 5000 meters (15000 feet) have been shown to induce sickling in two subjects with 
“probable sickle cell trait.”27  
The issue of sudden death during exercise in sickle cell trait carriers has been 
controversial.49-51 The first cases of sudden death attributed to exertional sickling were identified 
between March 1968 and February 1969 in U.S. army recruits during basic training at Fort Bliss, 
Texas.52 During this time period, four recruits died during or immediately after the strenuous 
exercise that is characteristic of basic training.  Autopsy reports on each recruit concluded that 
the cause of death was a result of diffuse microvascular obstruction from sickled erythrocytes.  
The elevation of Fort Bliss is 4,050 feet above sea level and considered a relatively high altitude 
where modest hypoxemia may occur.  Investigators speculated that the combination of altitude 
and strenuous exercise soon after arrival at basic training caused a decrease in blood oxygen 
levels leading to lactic acidosis, exertional sickling, and sudden death.  They added that other 
environmental stressors, including dehydration and increased blood viscosity, might have also 
been contributing factors. 
The most convincing data comes from a retrospective study from Kark and colleagues 
from the Army Medical Corps physicians, which reviewed all deaths amongst active-duty 
military between the years 1977 and 1981.53 The comprehensive review of 2 million enlisted 
recruits concluded that in black recruits with sickle cell trait (n=37,000) the risk of sudden 
unexplained death was estimated to be 30 times greater than that of black recruits without sickle 
cell trait (n=429,000) and 40 times greater than that of non-black recruits without sickle cell trait 
  13 
(n=1,620,000).  Among the black recruits with sickle cell trait, the rate of sudden death was 32.2 
per 100,000, compared to 1.2 per 100,000 in black recruits without sickle cell trait (n=429,000).  
As with the Ft. Bliss recruits, deaths tended to occur during the first month of training and were 
associated with training activities that required a maximal degree of effort.  Results similar to 
Kark’s study were demonstrated in a similar study of non-traumatic deaths in the US Air Force 
between the years 1956 and 1996.54 Compared to those without sickle cell trait, personnel with 
sickle cell trait had a relative risk for sudden death of 23.5 (95% CI, 19.5-30.0).   
In addition to the military data, there have been over 30 case reports documenting fatal or 
serious exercise-related complications in young black men with sickle cell trait.35 Just in the last 
decade 136 non-traumatic sports deaths were reviewed for high school and college athletes and 
exertional sickling was the proposed cause in seven (5%) of the cases.2 On the collegiate level, 
13 football players have reportedly died after collapse brought on by exertional sickling, with 
similar symptoms and settings.  The players participated in brief on-field drills, sprinting on 
average 800-1,600 meters, often early in the season, or in repetitive running of hills/stadium 
steps.  Sickling also occurred when the intensity of exercise increased late in practice or on a rare 
occasion, during a game.  In this scenario there was a sustained, constant action such as sprinting 
down the field.55 Reports are not isolated to football as several basketball players have died 
suddenly as well.  Please see Section 2.3.3 for the NCAA response to these deaths. 
The explanation of these deaths is not entirely clear. Although the majority of data 
indicates an association between sickle cell trait and sudden death there is no direct evidence of 
causation.  Autopsies on these individuals revealed sickling; however, Hb S polymerization 
occurs naturally postmortem and there is no method to discern postmortem and antemortem 
sickling.56 It has been suggested that the dehydration, hyperthermia and acidosis associated with 
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extreme physical exertion can cause Hb S polymerization, exertional sickling, which leads to 
vaso-occlusion and endothelial damage.  The results of these consequences include 
rhabdomyolysis (muscle break-down), acute renal failure and coronary vasoconstriction.35   
In response to the sudden death related to exertional heat illness in Army recruits, certain 
centers participated in an intervention to prevent additional deaths from occurring from 1982-
1991.57 The participating centers measured wet-bulb globe temperature (WBGT) at least hourly 
at the exercise site.  The WBGT is the composite temperature used to estimate the effect of 
temperature, humidity, wind speed, wind chill, and solar radiation on humans.  When the WBGT 
rose to 90ºF, exercise intensity was decreased and rest cycles were increased.  Measures were 
taken to observe water consumption and increase water intake as needed, as well use of light 
track clothing in hot weather to keep recruits from overheating.  If early symptoms of exertional 
heat illness presented, immediate cooling and re-hydration was initiated.  These precautions were 
taken for all of the recruits at a participating center. 
The number of deaths due to exertional heat illness which occurred at both participating 
and non-participating centers between 1982 and 1991 were compared to a predicted mortality for 
those years, based on previous years deaths (1977-1981).  Additionally, mortality rates were 
compared for recruits with and without sickle cell trait.  The results of the intervention were 
dramatic.  Observed deaths due to exertional heat illness at non-participating centers were not 
significantly different, regardless of recruits’ sickle cell trait status, when compared to predicted 
mortality rates.  At the participating centers, mortality due to exertional heat illness was reduced 
from the predicted 18.7 to 11 in recruits without sickle cell trait.  Amongst recruits with sickle 
cell trait 14.9 deaths were predicted; however, there were no reported exertional heat illness 
deaths in these recruits.57  
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The results of this intervention showed that exertional heat illness is a major preventable 
factor contributing to exercise-related death of young adults.  When these data were published, 
the authors concluded that there is a strong association between exposure to hot weather within 
24-hours of exercise and the risk of exercise-related sudden death, and this risk is even stronger 
for individuals with sickle cell trait.  Furthermore, the basic preventative measures taken during 
the intervention eliminated the excess risk for exercise-related death for those with sickle cell 
trait and was able to reduce mortality in those without sickle cell trait.57  
2.3 HISTORY OF SICKLE CELL TESTING 
2.3.1 Methods of Testing for Sickle Cell Disease and Trait 
Diagnosis of sickle cell disease and sickle cell trait does not require complex procedures.  As 
illustrated earlier by Pauling’s discovery, electrophoresis can distinguish sickle hemoglobin from 
normal hemoglobin; however, other methods exist which are broadly divided into the following 
categories: tests for sickle hemoglobin, methods for genotyping, and procedures for pinpointing 
the genetic sub-division of the major genotypes.27   
There are two tests that can be used to detect sickle hemoglobin.  The sickle test was the 
first method available for this purpose, in which a drop of blood is prepared on a microscope 
slide and sealed under a cover slip to isolate the sample from oxygen.  Within one hour, if sickle 
hemoglobin is present, the sickled cells are visible under a microscope.58 The second, newer 
method, is the solubility test (a version is marketed under the name Sickledex), which is utilized 
due to the relative insolubility of deoxygenated Hb S in solutions of high molarity.59 Using 
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buffers, lysing and reducing agents, samples with Hb S become cloudy and those without Hb S 
remain clear. While both methods reliably test for the presence of sickle cells, there is no 
situation in which a positive sickle cell or solubility test should be reported without follow-up 
from electrophoresis and complete blood count (CBC) as the major limitations of these earlier 
tests is their failure to differentiate between sickle cell trait and the clinically significant sickle 
cell anemia or other sickle cell disorders.27 
Hemoglobin electrophoresis is the method used to genotype the sickle cell disorders. This 
is the major technique used for diagnosis of sickle cell disease and trait.  It capitalizes on the 
changes that occur to the charge of the hemoglobin protein when amino acid substitutions occur. 
Each known hemoglobin variant has a characteristic position movement upon electrophoresis.  
For example, in conventional alkaline electrophoresis, due to the replacement of neutral valine of 
Hb A for negatively charged glutamic acid in the hemoglobin ß-chain in Hb S, Hb A moves 
more slowly than Hb S towards the anode.27  This method is limited in that it cannot distinguish 
hemoglobins that have amino acid substitutions resulting in the same charge.  To distinguish 
these changes, genetic mutation analysis or full gene sequencing is necessary.    
 
2.3.2 Sickle Cell Anemia Control Act 
In 1972 the Sickle Cell Anemia Control Act (P.L.92–294) was signed by into law by President 
Richard Nixon.  The motion pledged $10 million dollars to expand sickle cell programs for the 
year 1972 alone, a ten-fold increase from the year before, and $15 million dollars to be spent in 
1973.  The funds were approved to establish voluntary screening and counseling for sickle cell 
anemia, development and dissemination of educational materials for both health care personnel 
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and the general public, in addition to research for the diagnosis, treatment and “control” of sickle 
cell anemia.60 Screening was specifically targeted at those people of childbearing age or children 
under the age of seven.  While the act was intended to help increase funding for sickle cell 
anemia awareness and research, it also stirred controversy.  Genetic counseling was triumphed as 
an effective method to raise awareness and prevent disease; however, some saw it as the new 
eugenics.  Although the act suggested voluntary testing, some states had already or were 
considering making sickle cell anemia testing mandatory.61 Allegations were made that the act 
one of an assault against the African-American community and an effort to curb reproduction.61 
Sickle cell anemia advocates, patients and experts found themselves in a difficult 
position.  Howard Pearson, a pediatric hematologist, suggested that the controversial hype arose 
because, “education had been sorely neglected in the rush to run out and stick somebody and 
take his blood.”  The screening programs and genetic counseling services that were made 
available were hastily devised and executed without regard to privacy or awareness of the 
potential implications.  Later in 1972, Pearson went on to write, “Perhaps we should wait until 
we have more to offer these people before we go around handing out such information [of sickle 
cell trait status] so casually.”61  Furthermore, often times the sickle cell solubility test was used 
leading to confusion between sickle cell disease and trait.  The controversy has since subsided; 
however, tensions still remain.   
Stemming from the National Sickle Cell Anemia Control Act were advances in research 
for sickle cell disease, resulting in sickle cell disease no longer being a disease of childhood and 
extending lifespan for those affected, as well as statewide sickle hemoglobinopathy newborn 
screening programs. 
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2.3.3 Newborn Screening 
Currently, universal screening for sickle hemoglobinopathies exists in all of the newborn 
screening programs in the United States (all 50 states and the District of Columbia); however, 
this was not the case until relatively recently.  Although universal screening for sickle 
hemoglobinopathies was recommended by the National Institutes of Health in 1987, it took 
nearly 20 years for all screening programs to follow suit.62  Here in Pennsylvania, sickle 
hemoglobinopathies were added to the universal newborn screen in September 1992.  Shortly 
after birth a baby’s heel is pricked and the blood is collected on a blood filter paper card to create 
a dried blood spot.  This sample can then be used in an electrophoresis based procedure, called 
isoelectric focusing.  This test is used in most newborn screening laboratories, to test for the 
sickle hemoglobinopathies (another procedure used in some laboratories, similar in result is high 
performance liquid chromatography).  By law, if the result is positive for a sickle 
hemoglobinopathy, families must be contacted and proper medical measures must be taken.  In 
Western Pennsylvania, families are also notified by telephone and mail if their children are 
identified to have sickle cell trait. 
2.3.4 Military 
Each branch of the military maintains its own sickle cell trait screening guidelines and training 
procedures.  After the 1972 National Sickle Cell Anemia Control Act, the U.S. Air Force 
screened all recruits and restricted those with sickle cell trait from flying, based on the incorrect 
theory that the high altitude could cause them to go into a pain crisis.  This ruling further added 
to the controversy stemming from the act, with allegations of employment discrimination.  
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Currently the U.S. Airforce still screens all recruits; however, recruits with sickle cell trait are 
now given the option to decline service.  The Marines and the Navy also screen all recruits.  The 
Marines do not change training regimen for recruits with trait; however, the Navy identifies trait 
carriers with a red belt and neck tag during strenuous drills.  As of now, the Army is the only 
branch of the military not screening for sickle cell trait.56 
2.3.5 National Collegiate Athletic Association 
On June 29th 2009, the National Collegiate Athletic Association (NCAA) released a statement 
recommending that member colleges and universities test student athletes to confirm their sickle 
cell trait status if not already known.3 The recommendation was adopted by the NCAA 
committee on Competitive Safeguards and Medical Aspects of Sports, four days prior on June 
25th.  The action followed guidelines from National Athletic Trainers Association (NATA) and 
the College of American Pathologists (CAP), and stemmed from the recent resolution of a 
lawsuit brought against the NCAA by the family of Dale Lloyd II.   
Mr. Lloyd, who excelled at football and baseball his entire life, was offered an athletic 
scholarship as a freshman in 2006 to Rice University, a Division I school in Houston, Texas.63  
In late September, the day after a football game, Mr. Lloyd participated in a practice that 
included weight lifting and sixteen 100-yard sprints.  During the running portion of practice, he 
collapsed.  He died at the hospital the following day; the cause of death was determined to be 
rhabdomyolysis.  After his death, it was determined that he had sickle cell trait.  His death was 
unfortunately not the first of its kind in the field of competitive collegiate athletics.  His family 
stated that they were not aware of the potential dangers of having sickle cell trait and intense 
exercise, so they never thought it necessary to have their son tested for sickle cell trait.  While 
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they were not aware of the association, they argued that the NCAA was.   Legal action against 
the NCAA was pursued based on officials for not taking any precautionary measures to protect 
student athletes and promote awareness as to the potential harm associated with sickle cell trait 
in athletics.63  
The lawsuit settled in 2009, included a $50,000 donation from the NCAA to the Sickle 
cell Disease Association in the name of Dale Lloyd II to be used to fund awareness, education, 
and screening for sickle cell trait in the athletic population, as well as a $10,000 donation to the 
Dale Lloyd II scholarship fund.3 As part of the settlement the NCAA agreed to recommend that 
its participating member colleges and universities screen all athletes for sickle cell trait.  The 
amendment is stated in the NCAA Sports Medicine Handbook Guideline 3c as, “that while sickle 
cell trait screening is normally performed on all U.S. babies at birth, some student athletes may 
not know if they have trait.  Following recommendations from NATA and CAP, the NCAA 
recommends athletic departments confirm sickle cell trait status in all student athletes, if not 
already known, during their required medical examinations.” The NCAA also agreed to stress 
this point during regular media communication during 2009 football preseason and the football 
rules book (Table 1).  Additionally, the NCAA agreed to prepare an educational video about 
sickle cell trait to be made available on its website and to member schools.3 Before the lawsuit, 
64% of colleges were already screening for sickle cell trait.63    
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Table 1: NCAA Guidelines for Student Athletes With Sickle Cell Trait 
Athletes with sickle cell trait should: 
• Set their own pace 
• Engage in a slow and gradual preseason conditioning regimen to be prepared for sports-specific 
performance testing and the rigors of competitive intercollegiate athletics 
• Build up their intensity slowly while training 
• Use adequate rest and recovery between repetitions, especially during “gassers” and intense 
station or “mat” drills 
• Not be urged to perform all-out exertion of any kind beyond 2-3 minutes without a breather 
• Be excused from performance tests such as serial sprints or timed mile runs, especially if these are 
not normal sport activities 
• Stop activity immediately upon struggling or experiencing symptoms such as muscle pain, 
abnormal weakness, undue fatigue or breathlessness 
• Stay well hydrated at all times, especially in hot and humid conditions 
• Maintain proper asthma management 
• Refrain from extreme exercise during acute illness, if feeling ill, or while experiencing a fever 
• Access supplemental oxygen at altitude as needed 
• Seek prompt medical care when experiencing unusual distress 
 
2.3.6 Comparison to Other Health Conditions 
The leading cause of death in athletes during sport-related activities is sudden cardiac arrest from 
occult cardiovascular disease.64 Several congenital or acquired cardiac malformations account 
for the majority of these deaths in United States athletes aged 35 and younger.  Hypertrophic 
cardiomyopathy is the single most common cause (36%), followed by congenital coronary artery 
anomalies (17%).65 In the United States, these deaths occur most commonly in basketball and 
football, as these sports have the highest levels of participation, as well as including particularly 
intense levels of physical activity.66 Similar to sickle cell trait in athletics, sudden cardiac death 
in a young athlete often generates a high public profile because of the youth or celebrity of 
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victims and the belief that athletes are amongst the healthiest in our society.  As a result, 
cardiovascular screening for athletes is routinely practiced and performed by most major sporting 
associations, including the International Olympic Committee and the NCAA.  
The NCAA Committee on Competitive Safeguards and Medical Aspects of sports 
mandates a preparticipation evaluation for all Division I, II, and III athletes before their first 
practice or competition.  Further recommendation is that these evaluations be performed or 
supervised by a qualified physician, and evaluations is based on gathering a cardiovascular based 
family history and physical examination.67  In contrast to sickle cell trait testing, these methods 
are considerably less invasive, as they are verbal and examination based.  The evaluation in the 
NCAA is based upon American Heart Associations (AHA) Recommendations for 
Cardiovascular Screening of Competitive Athletes (Table 2), and only omits the medical history 
question regarding fatigability and Marfan stigmata on examination.65 
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Table 2: The 12 Element AHA Recommendations for Preparticipation Cardiovascular Screening of 
Competitive Athletes 
Medical History 
Personal history 
       1. Exertional chest pain/discomfort 
                   2. Unexplained syncope/near syncope 
       3. Excessive exertional and unexplained dyspnea/fatigue, associated     
         with exercise 
       4. Prior recognition of a heart murmur 
       5. Elevated systemic blood pressure 
Family History 
       6. Premature death (sudden and unexpected, or otherwise) before age       
           50 years due to heart disease, in ≥1 relative 
       7. Disability from heart disease in a close relative <50 years of age 
       8. Specific knowledge of certain cardiac conditions in family  
           members: hypertrophic or dilated cardiomyopathy, long QT  
           syndrome or other ion channelopathies, Marfan syndrome, or  
           clinically important arrythmias 
Physical Examination 
        9. Heart murmur 
      10. Femoral pulses to exclude aortic coarctation 
      11. Physical stigmata of Marfan syndrome 
      12. Brachial artery blood pressure (sitting position). 
 
 There have been several high profile cases involving cardiac sudden death in basketball, 
including the untimely on-court deaths Loyola Marymount star Hank Gathers in 1990 and 
Boston Celtics guard Reggie Lewis in 1993, both of whom collapsed and died, due to 
undiagnosed hypertrophic cardiomyopathy.68 In 2005, a controversy brewed over Chicago Bulls 
player Eddy Curry, who missed several games due to an irregular heart beat.  Doctors could not 
determine the cause.  He received clearance from two separate cardiologists to play, but there 
was still concern that he could be susceptible to hypertrophic cardiomyopathy.  The general 
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manager, John Paxson, offered him a long-term contract to play on the condition that Curry take 
a DNA test to gauge his susceptibility to HCM.  If it was discovered that Curry did have a 
mutation, then he would be offered $400,000 for 50 years not to play basketball.68, 69 Curry 
rejected the deal and refused testing stating that the test would only gauge his susceptibility to 
sudden cardiac arrest and was not definitive.  He was subsequently traded from the Bulls to the 
New York Knicks, who did not require him to take a genetic test.   
 While there has not been a similar situation relating to sickle cell trait, lessons need to be 
learned from the case of Eddy Curry and the controversy stemming from the National Sickle Cell 
Control Act.  Mandatory genetic testing can be very unsettling, especially if it is not approached 
with the appropriate amount of care and education.  It is with this in mind that our team set out to 
create a methodology to provide adequate education and awareness regarding sickle cell trait 
amongst student athletes and the athletic staff at the University of Pittsburgh, in addition to 
voluntary genetic testing that ensured autonomy, beneficence, and protection of health.  
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3.0  SPECIFIC AIMS 
3.1 SPECIFIC AIM 1 
Specific Aim 1: To provide voluntary sickle cell trait testing to interested student athletes at the 
University of Pittsburgh, in concordance with the ethical principles of genetic testing: autonomy, 
beneficence (non-malfeasance), and protection of health. 
 
Plan: To enable student athlete autonomy and ensure that testing is offered on a voluntary basis.  
Privacy is provided to the best of our abilities, by reporting the test result only to the athlete; 
however, as it is part of their medical record, the athletic staff also gains knowledge of their test 
result.  Finally, to provide an environment of non-malfeasance, which ensures that the university 
will only use this information for the good of the athlete and not discriminate against any athlete 
who has newly identified sickle cell trait. 
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3.2 SPECIFIC AIM 2 
Specific Aim 2: To educate staff and student athletes about the potential complications of sickle 
cell trait in athletics, how to avoid these complications and prevent sudden death in the student 
athlete. 
 
Plan:  Provide counseling and education to the student athletes prior to testing, in addition to 
post-test follow up to answer any remaining questions.  For the athletic staff, athletic trainers, 
and coaches, provide extensive education regarding the historical significance of sickle cell trait; 
the proposed physiology of exertional sickling; and methods to prevent and treat exertional 
sickling to avoid sudden death in the student athlete. 
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4.0  PROGRAM DESIGN 
4.1 COLLABORATION WITH THE UNIVERSITY OF PITTSBURGH 
In July of 2009, the University of Pittsburgh Department of Athletics contacted The Children’s 
Sickle Cell Program at Children’s Hospital of UPMC regarding testing its athletes for sickle cell 
trait due to the NCAA’s recent recommendations to its members to test student athletes for sickle 
cell trait.  The Department of Athletics was seeking information as to how to facilitate and 
proceed with testing.  Before initial contact contact, we were aware of the NCAA’s 
recommendations and were in the process of devising a testing strategy for use in the university 
setting to ensure that should testing occur it be performed ethically, and abide by the principles 
of genetic testing; autonomy, beneficence, accuracy and privacy.   
We offered our clinical services to the University of Pittsburgh to provide testing 
services, in addition to pre- and post- test counseling to the student athletes, and education for 
athletes and athletic staff.  We had many discussions with the University of Pittsburgh, 
specifically with the athletic training coordinator, Mr. Tony Salesi, as to how testing should best 
be performed to meet the University of Pittsburgh’s individualized needs, while maintaining 
student athletes’ privacy, autonomy and preventing any discrimination regarding results of the 
test.  The University of Pittsburgh elected to inform their athletes of the NCAA 
recommendations and offer testing on a voluntary basis.  We worked with them to set up five 
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separate times over the course of three weeks to come to the athletic training facilities and 
provide pretest counseling, education, and testing.  
 The University of Pittsburgh was willing to cover the cost of testing each of its student 
athletes for sickle cell trait.  Our program provided our staff’s time at no cost and was able to 
offer them the test for $12.50 each.  This test was billed through each student athlete’s insurance 
plan, provided by and paid for by the University of Pittsburgh.  We provided their insurer the 
current procedural terminology (CPT) code for billing (Table 3).  IRB approval was not sought 
for this project, as being a clinical service, does not meet the definition of research.  
Table 3: Explanation of CPT Codes 
CPT Codes Explanation 
83021 hemoglobin chromatography 
85014 Hematocrit 
85018 Hemoglobin 
85041 red blood cell count 
4.2 ATHLETE PRE-TEST COUNSELING AND EDUCATION 
Prior to arriving at the athletic training facilities on the University of Pittsburgh’s campus, the 
athletes had been informed about the availability of voluntary testing either by their coaches or 
by volunteers during their physical examinations.  The athletes were given a form to sign if they 
elected to be tested for sickle cell trait (Appendix A).  Athletes who decided to have testing for 
sickle cell trait were then informed of the available testing times.  Seventy-nine athletes elected 
to pursue testing (Table 4). 
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During testing sessions, athletes were given sickle cell disease and trait education, and 
counseling on an individualized basis (Appendix B).  We provided education materials, which 
included; a handout we created detailing the NCAA’s recommendations and the association 
between sickle cell trait and sudden death in the athlete, NATA’s training recommendations 
regarding SCT and the athlete, and pamphlets explaining sickle cell trait (Appendix B).  
Explanations of all of these materials were provided at length, and not limited only to sickle cell 
trait and the athlete, but also included the inheritance of sickle cell trait.  Additional materials 
were on hand regarding other hemoglobinopathies that could be found through testing, such as 
thalasemia. Approximately five minutes was spent on pre-test counseling and education with 
each athlete. 
Table 4: Composition of Student Athletes Electing Testing for Sickle Cell Trait by Sport 
Sport Number Tested 
Football 15 
Women’s Soccer 15 
Women’s Basketball 11 
Men’s Soccer 11 
Swimming & Diving 8 
Track & Field 5 
Men’s Basketball 4 
Softball 3 
Cross Country 3 
Cheerleading 2 
Other 2 
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4.3 HEMOGLOBINOPATHY TESTING  
All samples were collected on site at the University of Pittsburgh’s athletic training facilities, 
immediately after pre-test genetic counseling and education was completed.  We provided a 
registered nurse to perform phlebotomy services.  The nurse performed phlebotomy adhering to 
sterile standard procedure, and collected 2 mL of blood in a sterile lavender-top EDTA collection 
vial (BD Vacutainer, 5.4 mg EDTA).  The samples were transported back to Children’s Hospital 
of Pittsburgh of UPMC diagnostic laboratories within 2-6 hours of collection.  All samples 
collected underwent standard hemoglobinopathy evaluation via electrophoresis and whole red 
blood cell count. 
4.4 RESULT DISCLOSURE AND POST-TEST COUNSELING 
Athletes were notified within two to three weeks of their test date to disclose the result of their 
hemoglobinopathy evaluation.  All results were reported.  Each athlete was contacted by 
telephone for results disclosure and post-test counseling was provided at this time.  The athletes 
were given the option to arrange a meeting time if they desired further counseling or had 
additional questions.  If an athlete was unable to be reached by telephone after three attempts, an 
e-mail containing the test results were sent to the athlete, with a request for a return e-mail to 
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confirm that the athlete had received the test result and had no further questions.  All positive 
results were able to be given over the telephone, only negative results were e-mailed if need be.   
 Once the student athletes had been notified of their test results, the results were given to 
the University of Pittsburgh’s training staff.  As student athletes at the University of Pittsburgh, 
paricipants give the university permission to view all medical information.  The athletes were 
aware that the University of Pittsburgh would also know the results of their hemoglobinopathy 
evaluation.   
4.5 STAFF EDUCATION    
Approximately 6 weeks after testing commenced, our program met with members of the 
coaching, training and athletic staff to provide further education regarding sickle cell disease, 
sickle cell trait, the NCAA’s recommendations, and preventative measures that can be taken to 
ensure the safety for all athletes, regardless of sickle cell trait status (Appendix C).   
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5.0  RESULTS 
5.1 ATHLETE TESTING AND RESULTS DISCLOSURE 
Over the course of the testing sessions, 79 student athletes from the University of Pittsburgh 
elected to have sickle cell trait testing.  Athletes from a diverse group of sports were interested 
and we had participation from the football, softball, the men’s and women’s soccer teams, 
swimming, track and field, cross country and the men’s and women’s basketball teams.  The 
population of student athletes also varied in terms of gender and race/ethnicity.   
All results were reported directly to the student athletes.  Two athletes were found to have 
sickle cell trait.  After results disclosure, student athletes were asked if they would like to have a 
personal counseling session to speak further; however, no student athletes elected to pursue this 
option.  Athletes were given ample time to ask any questions they may have had about their 
result.  In some cases a finding indicated that further testing was needed.  Athletes with anemia 
or microcytic anemia were encouraged to follow-up with their primary care physician for further 
evaluation.  Microcytic anemia can be an indication of alpha-thalassemia trait and requires 
further evaluation.  Abnormal test results were also sent directly to the athletes with a letter 
explaining the sickle cell trait results and reproductive consequences, including risk and testing 
options.  Athletes were instructed to keep with this letter with their medical records. 
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5.2 RESPONSE FROM THE ATHLETIC STAFF 
We received a positive response from the members of the athletic staff.  When coordinating 
testing, all staff were eager to aid and assist us.  They were appreciative of our presence and 
seemed interested in learning more about sickle cell trait and methods to prevent exertional 
sickling.  During our educational presentation on sickle cell trait, the staff expressed interest and 
asked thoughtful, pertinent questions.  The athletic trainers, in particular, were extremely aware 
of the needs of their athletes.  We discussed at length the WBGT, with which the athletic trainers 
were familiar with, and they planned to incorporate the WBGT into their standard practice.  We 
also addressed the difficulties of wanting to push students physically to make them better athletes 
and improve their performance, but at the same time keep them safe. 
Our project found that the University of Pittsburgh Department of Athletics understood 
the potential adverse effects of testing athletes for sickle cell trait and agreed that merely testing 
student athletes is only a first step.  General changes can be made to the training environment to 
keep all athletes safe, regardless of their sickle cell trait status.  In conversations occurring after 
testing and results disclosure, the athletic training coordinator summed it up well by stating that, 
“The knowledge has made all individuals within our performance team more aware of potential 
issues and how we need to address them if a situation would arise.” 
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6.0  DISCUSSION 
6.1 SPECIFIC AIM 1 
This project set out to develop a comprehensive method of testing and genetic counseling for 
student athletes regarding sickle cell trait.  The project sought to incorporate the principles of 
genetic testing to ensure autonomy, beneficence and privacy.  We were able to maintain student 
athlete autonomy as testing was offered on a strictly voluntary basis.  The athletes did not appear 
to be coerced into testing, as not all athletes at the university elected to have testing.  It would be 
beneficial in the future to assess why athletes did not elect to have testing.  Possible explanations 
might include fear of discrimination, awareness of their trait status, lack of knowledge regarding 
sickle cell trait, or other unforeseen reasons.  While all the athletes we spoke to denied any 
anxiety regarding testing, we were only in contact with those student athletes who elected to 
have testing and for only a brief period of time.  
The results of the sickle cell trait testing did not result in any reported or observed harm 
to the athletes.  When queried, the University of Pittsburgh athletics staff reported that the 
athletes that were found to have sickle cell trait were still playing for their respective teams and 
were not being treated differently; however, they did note that they encouraged these athletes to 
notify the athletic trainers of any fatigue, muscle cramps, or aches during training.  Concerns 
about the possibility that athletes who tested positive for sickle cell trait may see less play time, 
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face stigmatization, or have scholarships revoked was unfounded.  Providing adequate education 
regarding sickle cell trait should prevent any undesirable implications from occurring, and it 
appears as if the project succeeded.  Again, since this was not a research study, but a clinical 
service, data were not able to assess or prove this conclusion.  In the future, it would be 
beneficial to survey athletes who are found to have sickle cell trait to discern any changes in how 
they were treated by athletic staff and regarding the amount of practice or competition time they 
encounter.   
Student athlete health protection and privacy was also a concern.  Initially we had 
planned to only report the test result to the student athlete and then let it be their decision if they 
wished to inform the athletic staff at the University; however, this was not possible, as the 
athletes sign a waiver at the beginning of their relationship with the University, allowing the 
University access to all of the student’s medical records.  This appears to be a routine collegiate 
athletics procedure, as the athletic staff is concerned about the well being of their athletes.  
Athletes were reminded of this agreement prior to testing. 
To ensure that the athletes had proper post-test counseling, we contacted them with their 
test results over the telephone, before releasing their result to the University.  While this method 
worked well, it was very time intensive to contact every student athlete over the telephone.  
Additionally, leading a student lifestyle, the athletes were not always the easiest to access and 
multiple telephone messages had to be left for many of the student athletes.  In the future, 
especially if more athletes elect to pursue sickle cell trait testing, perhaps only abnormal results 
should be called out to facilitate post-test counseling, and normal results could be mailed through 
the post or electronically.   
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6.2 SPECIFIC AIM 2 
Testing student athletes for sickle cell trait and providing education to the coaches needed to 
occur in tandem to gain the most from the testing process.  We were able to achieve this goal; 
however, in future initiatives the educational process could be restructured.  Education was 
provided to the athletes after they had already elected to have testing and occurred during pre-
test counseling.  While the athletes were given some information regarding sickle cell trait from 
the University of Pittsburgh before opting to have testing, it may be more beneficial for our team 
to speak with the athletes directly before they have to decide about testing.  This approach had 
been discussed initially with the athletic department, with our suggestion that we could speak for 
five to ten minutes at the beginning of practice for each team.  Our contact at the University of 
Pittsburgh indicated that while that might be possible, it would be difficult to get that amount of 
time from each individual coach, as they typically have an agenda at each practice and use every 
minute.  Our inability to meet with the athletes may have partly been due to the short time frame 
with which we had to work.  When planning for the Fall 2010 preseason months in advance, it 
may be possible to work out a time to meet with the teams individually.  If it is still not possible 
to meet with the teams before they have to decide to elect testing or not, then the University of 
Pittsburgh Department of Athletics will be provided with comprehensive educational materials to 
distribute to the teams, which will be reviewed at the time of testing. 
Additionally, as this project was not research based, we were not able to quantify or 
assess if any lasting changes had occurred or if there was a significant gain of knowledge as a 
result of the project.  This is an area that should be targeted in future studies.  It would be 
beneficial to survey the athletes before and after testing in regards to the basics of sickle cell 
disease/trait (including reproductive risks) and measures that can be taken to prevent exertional 
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sickling.  This method would allow us to determine how much the athletes knew before testing 
and how much information they retained after testing.  A similar assessment of knowledge 
should also be taken amongst the coaches and athletic trainers; however, with more emphasis on 
how to prevent and treat an exertional sickling crisis.  It would also be interesting to determine if 
awareness of sickle cell trait in the field of athletics grows from this point forward based on our 
initiative.  By assessing how much knowledge is already known and how much is retained, we 
can better target educational efforts to provide the maximum benefit in the field of collegiate 
athletics. 
6.3 FUTURE OF SICKLE CELL TRAIT TESTING IN THE NCAA 
The NCAA is currently in the process of deciding if it should amend its bylaws to mandate sickle 
cell trait testing.  In a document dated January 26th, 2010 the NCAA Division I Legislation 
Counsel proposed and amendment to its bylaws that, “prior to participation in any practice, 
competition or out-of-season conditioning activities (or in Division I, permissible voluntary 
summer conditioning in basketball and football or voluntary individual workouts pursuant to the 
safety exception), student athletes who are beginning their initial season of eligibility and 
students who are trying out for a team shall be required to undergo a medical examination or 
evaluation administered or supervised by a physician (e.g., family physician, team physician). 
The examination or evaluation shall include a sickle cell solubility test (SST), unless documented 
results of a prior test are provided to the institution.70”  The proposal was submitted for 
consideration on October 20th, 2009, forwarded for membership comment and received 
legislative council initial review on January 13th, 2010.  A comment period was open from 
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January 17th, 2010 and closed on March 17th, 2010; there has been no public release at this time 
as to whether the amendment has passed; however, if passed it will go into effect on August 10th, 
2010.70 
If the NCAA elects to make sickle cell trait screening mandatory, it should proceed with 
extreme caution, as mandatory genetic testing without consideration of the issues of autonomy, 
beneficence and privacy can be dangerous.  Additionally, the use of the sickle cell solubility test 
instead of hemoglobin electrophoresis along with complete blood count is concerning.  While the 
sickle cell solubility tests is marginally less expensive that electrophoresis with complete blood 
count ($10 compared to $12-$15), it does not give the complete picture or most accurate result.  
If student athletes are administered the test and simply told that they do or do not have sickle cell 
trait, without further explanation, they may have misconceptions as to their future reproductive 
risks or carry the trait for other sickle hemoglobinopathies.  If they are an undiagnosed carrier, 
they would have a 25% chance to have a child with sickle cell disease, should their partner also 
be a carrier of sickle cell trait.   
Furthermore, there is no mention of education or genetic counseling in the NCAA’s 
proposed plan.  If neither are provided along with the sickle cell trait screening, merely 
determining if an athlete has sickle cell trait is not sufficient to protect them from potential harm.  
As the military data suggests, the most effective way to reduce exercise-related death is to follow 
conditioning guidelines that provide adequate hydration and prevent overheating, to reduce the 
risk of death for all athletes, regardless of sickle cell trait status.  Reassurance that the risk of 
sudden death is very low should be stressed in all discussions.  If a student athlete does not 
understand the reasoning behind testing the athletic staff may intentionally or unintentionally 
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discriminate against athletes with trait, resulting in a backlash against testing, doing much more 
harm than good.   
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7.0  CONCLUSION 
In conclusion, this project was successfully met its specific aims.  The project provided a 
comprehensive testing program for sickle cell trait, one in which education and genetic 
counseling were both provided, which could be individualized to the needs of a university.  
Testing was done in concordance with the principles of genetic testing; autonomy, beneficence, 
and privacy.  Within the University of Pittsburgh Department of Athletics we were able to 
achieve these aims and developed a useful working relationship with the athletic department 
there.  This collaboration represents the beginning of a lasting relationship that should continue 
to be successful in the future.  Additionally our team is currently speaking with other universities 
in the area to provide testing and education as well.  It is encouraging that the universities in the 
area are motivated to provide the best care for their athletes.  By forging additional relationships 
with area universities and improving our educational efforts, we will be able to better raise 
awareness regarding sickle cell trait in the field of athletics, hopefully preventing any sudden 
death in otherwise healthy, young athletes.   
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APPENDIX A 
UNIVERSITY OF PITTSBURGH’S FORM FOR VOLUNTARY SICKLE CELL TRAIT 
TESTING 
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University of Pittsburgh 
 
Sickle cell trait Screening Form 
 
TO THE STUDENT ATHLETE:  PLEASE READ THIS CAREFULLY.  IF YOU HAVE 
ANY QUESTIONS REGARDING THIS FORM, PLEASE ASK AN ATHLETIC TRAINER TO 
REVIEW IT WITH YOU AND EXPLAIN ITS CONTENTS. 
_________________________ 
Print Name 
 I understand that I could be at risk of physical, and potentially life-
threatening, problems, if I have an inherited condition known as sickle cell trait and I 
participate in certain activities as a student athlete.  I have read and understood the 
section titled “The Student athlete with Sickle cell trait” from the 2009-10 NCAA Sports 
Medicine Handbook, which is attached to this form.  I have had the opportunity to ask 
questions of the University of Pittsburgh’s athletics trainers about sickle cell trait, and 
the screening for sickle cell trait, and all questions I have were answered to my 
satisfaction and in a way I understand. 
 I understand a simple blood test is available to determine if I have sickle 
cell trait.  I understand that the University of Pittsburgh STRONGLY RECOMMENDS 
that I have the test done, and that it is available at no cost to me.   
My signature below signifies that (choose one): 
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 A. I decline to have the test done at this time in spite of the 
University’s recommendation and in spite of the potential risk to me.  I understand the 
University will continue to make the test available at no cost to me, as long as I am a 
student athlete at the University, provided I later inform a University athletics trainer that 
I then wish to be tested. 
____________________________
__ 
Signature:  Student athlete 
 
 
____________________________
__ 
Signature:  Parent/Legal Guardian 
                     (if under age 18) 
 
 
____________________________
__ 
Signature:  Witness 
 
____________________ 
Date 
 
____________________ 
Date 
 
 
____________________ 
Date 
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 B. I wish to proceed to have the test done at no cost to me. 
 
 
____________________________
__ 
Signature:  Student athlete 
 
____________________________
__ 
Signature:  Parent/Legal Guardian 
                     (if under age 18) 
 
____________________________
__ 
Signature:  Witness 
 
 
 
____________________ 
Date 
 
____________________ 
Date 
 
 
____________________ 
Date 
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APPENDIX B 
EDUCATIONAL MATERIALS PROVIDED TO STUDENT ATHLETES AT THE 
                 UNIVERSITY OF PITTSBURGH PRIOR TO TESTING
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Hemoglobin S Trait and YOU, the Athlete 
…The importance of getting tested… 
 
New NCAA Recommendations 
The National College Athletic Association (NCAA) recently began recommending that all of its 
athletes be tested for hemoglobin S trait, also known as Sickle cell trait.  This recommendation is 
made due to the fact that “exertional sickling” a complication of sickle cell trait is the leading 
cause of death among NCAA football players this decade.  One can be tested for hemoglobin S 
trait with a simple blood test. 
 
Where does your hemoglobin come from? 
Your hemoglobin type is inherited through family genes.  The color of your hair, the color of 
your eyes, your body build and your hemoglobin type are all examples of things about you that 
are determined by genes.  You receive one gene for hemoglobin type from your mother and on 
from your father. 
 
Hemoglobin A or normal adult hemoglobin is the most common type.  There are more that 500 
different types or variations of hemoglobin. 
 
What is Hemoglobin S Trait? 
Hemoglobin S is often found in African Americans.  It is common in people of African, 
Mediterranean, Middle Eastern and Indian origin.   
 
Hemoglobin S behaves differently than normal hemoglobin A.  Red cells with mostly 
hemoglobin S can become hard and sickle-shaped.  People with hemoglobin S trait inherit a 
normal hemoglobin gene (HbA) from one parent and a hemoglobin S gene (HbS) from the other 
parent.  This results in hemoglobin AS or hemoglobin S trait.   
 
Hemoglobin S trait is not a disease.  It will not turn into a disease.  Hemoglobin S trait only 
causes health problems under extreme conditions, when this happens it is called exertional 
sickling.   
 
What is exertional sickling? 
Under intense exercise, red blood cells with hemoglobin S change from round to quarter-moon 
shaped, this is called sickling.  These sickled cells do not pass through the blood vessels as easily 
as round cells and can cause the vessels to become jammed, posing a grave risk for the athlete.   
 
How can exertional sickling be prevented? 
Although exertional sickling is a serious condition, it can easily be prevented if it is known that 
one has hemoglobin S trait.  It is recommended that athletes with hemoglobin S trait be allowed 
to acclimate themselves gradually to strenuous drills, set their own pace and drink plenty of 
water.  If these guidelines are followed, exertional sickling can be completely avoided. 
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APPENDIX C 
PRESENTATION GIVEN TO THE ATHLETIC STAFF AT THE UNIVERSITY OF
                                   PITTSBURGH 
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